A sleepy society of retired seniors is shaken up one morning by the murder of one of their neighbours. An elderly woman has been killed in broad daylight. Veteran inspector Jayant Shevde is called to the spot and he soon discovers a second body: An unknown Englishwoman was also murdered within the society premises. Who could have done this? And why? As Shevde investigates the double homicide, he realises that there appears to be no connection between the two. He chases one evidence to the next only to reach a dead end. Meanwhile, someone is hell-bent on erasing all the evidence linked to the case. Can Inspector Shevde solve one of the most intriguing cases of his career? Read Wrong Time to Shoot to find out.
A sleepy society of retired seniors is shaken up one morning by the murder of one of their neighbours. An elderly woman has been killed in broad daylight. Veteran inspector Jayant Shevde is called to the spot and he soon discovers a second body: An unknown Englishwoman was also murdered within the society premises. Who could have done this? And why? As Shevde investigates the double homicide, he realises that there appears to be no connection between the two. He chases one evidence to the next only to reach a dead end. Meanwhile, someone is hell-bent on erasing all the evidence linked to the case. Can Inspector Shevde solve one of the most intriguing cases of his career? Read Wrong Time to Shoot to find out.
At a time when the field of cardiac safety is going through important changes, this unique book provides the rationale for, and cutting-edge explanations of, new regulatory landscapes that will likely govern cardiac safety assessments globally for the foreseeable future. Exposure-response modeling is already being accepted by regulatory agencies in lieu of the traditional Thorough QT/QTc Study, and the Comprehensive in vitro Proarrhythmia Assay initiative is well under way. Developments in the field of cardiovascular safety are also described and discussed in the book. These include the search for more efficient ways to exonerate new drugs for type 2 diabetes from an unacceptable cardiovascular liability, how best to address off-target blood pressure increases induced by noncardiovascular drugs, and the continued evolution of the discipline of Cardio-oncology. “a resource that will likely serve as a standard for years to come” - Dr Jonathan Seltzer Therapeutic Innovation & Regulatory Science, 2017;51(2):180 “I have no hesitation in recommending this book as a valuable reference source” - Dr Rashmi Shah Journal for Clinical Studies, 2017;9(1):62-63
Thank you for visiting our website. Would you like to provide feedback on how we could improve your experience?
This site does not use any third party cookies with one exception — it uses cookies from Google to deliver its services and to analyze traffic.Learn More.